TASE offers covered options

The new product comes as part of TASE's strategy to offer an increasing number of vehicles to allow Israeli investors to diversify worldwide.

By ZEV STUB
April 6, 2006 07:43

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Tel Aviv Stock Exchange said Wednesday it has begun offering covered options on the exchange. The first options, in oil commodities, were sold Tuesday by Excellence Nessuah. Covered options are backed by the underlying shares or commodities underlying the option, and are sold to hedge risk in investments. The new product comes as part of TASE's strategy to offer an increasing number of vehicles to allow Israeli investors to diversify worldwide. The exchange noted that Israelis can invest locally in securities tracking 37 indices from world markets. More than $300 billion of covered options are currently sold in markets around the world, the TASE said.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS